Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Novo Nordisk Extends Lead As Eli Lilly New Obesity Pill Sees Modest Launch Uptake
12:04pm, Friday, 17'th Apr 2026
Reuters, citing IQVIA data, reported that Eli Lilly recorded 1,390 prescriptions for its newly launched obesity pill in the U.S. for the week ended April 10.
3 Ways to Invest in the Growing GLP-1 Weight Loss Market
11:20am, Friday, 17'th Apr 2026
Weight loss drugs are big business, with the GLP-1 receptor agonist market expected to nearly triple in size to $185 billion by 2033, a compound annual growth rate of about 12.4%. Although increasingl
Should You Forget CVS Health and Invest in a Purer Healthcare Play?
02:00pm, Thursday, 16'th Apr 2026
CVS Health has a far more diversified business than Novo Nordisk. Both approaches have perks and disadvantages.
Novo weight-loss drug may preserve lean body mass better than Lilly's, study finds
12:21pm, Thursday, 16'th Apr 2026
Eli Lilly's GLP-1 drug tirzepatide yields greater weight loss on average than Novo Nordisk's semaglutide, but at a greater expense to muscles and connective tissues, according to a study publish
NVO Inks Deal With OpenAI for Speedy Drug Discovery Globally, Stock Up
11:20am, Wednesday, 15'th Apr 2026
Novo Nordisk stock up as it teams up with OpenAI to deploy AI across drug discovery and operations, aiming to speed therapies, boost efficiency and counter rising competition.
Novo Nordisk weight-loss drug shows liver benefits in mouse study
07:28am, Wednesday, 15'th Apr 2026
GLP-1 drugs have direct beneficial effects on the liver, independent of their benefits for obesity, researchers studying the medicines in mice with fatty liver disease have found.
Novo Resources Strengthens Exploration Leadership with Appointment of Experienced Geologist Mr. Rohan Williams
04:30pm, Tuesday, 14'th Apr 2026
PERTH, Australia, April 14, 2026 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO) (OTCQX: NSRPF) is pleased to announce that Mr. Rohan Willams, an experienced Expl
Novo Nordisk CEO: This is where science meets speed and scale
02:48pm, Tuesday, 14'th Apr 2026
Maziar Mike Doustdar, CEO of Novo Nordisk, says AI partnership with OpenAI will speed drug discovery and delivery, boost accuracy and strengthen confidence in Wegovy despite rising competition.
Baird International And Global Growth Funds Q1 2026 Portfolio Activity
01:06pm, Tuesday, 14'th Apr 2026
ASML reported solid 4Q25 results and record bookings due to strong AI demand for DRAM and advanced logic, and FY2026 guidance is above consensus. Adyen reported December quarter results slightly below
Big Pharma Deepens AI Ties. What It Means For Novo, Novartis.
12:52pm, Tuesday, 14'th Apr 2026
Novo Nordisk and Novartis deepened their ties to AI companies on Tuesday.
Move Over Novo Nordisk - This Small Company Study Flags Edge In Fatty Liver Drug
12:30pm, Tuesday, 14'th Apr 2026
The HT-VA study demonstrated that parenteral GDNF (Glial Cell-Derived Neurotrophic Factor) significantly reduces fat production and enhances fat metabolism at the genetic level, positioning it as a un
Does NVO Face Rising Competitive Pressure on LLY's Foundayo Approval?
11:21am, Tuesday, 14'th Apr 2026
Novo Nordisk faces rising pressure as LLY launches Foundayo, a rival obesity pill, challenging Wegovy despite data suggesting NVO's edge in efficacy.
Novo Nordisk: Intense Competition Within The GLP-1 Duopoly
10:20am, Tuesday, 14'th Apr 2026
Novo Nordisk reached an all-time high of $148.15 in June 2024, when market participants were widely optimistic about the prospects of NVO's new semaglutide drug for weight management, Wegovy. After a
Live Nasdaq Composite: Markets Extend Rebound, Oil Slips in Pivot Toward Tech Deals
10:19am, Tuesday, 14'th Apr 2026
Live Updates The analyst who called NVIDIA in 2010 just named his top 10 AI stocksWall Street is pouring billions into AI, but most investors are buying the wrong stocks. The analyst who first identif
Stock Market Today (LIVE): PPI Beats Fear, But Oil Risks Loom; Novo's OpenAI Deal Lifts Shares
09:33am, Tuesday, 14'th Apr 2026
Top insights from the latest market news from Tuesday, April 14, from The Motley Fool analysts on Team Rule Breakers and Team Hidden Gems.
